Acurx registers 1.5M shares for Lincoln Park resale
ACXP registers 1.5 million shares for resale tied to its $12 million equity facility with Lincoln Park, leaving about $2.8 million of potential future funding.
Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
S-1
Rhea-AI Filing Summary
Acurx Pharmaceuticals, Inc. (ACXP) filed a Form S-1 to register 1,500,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing equity purchase agreement. These shares may be issued to Lincoln Park at Acurx’s discretion over a 24‑month term.
Acurx is a late-stage biopharmaceutical company developing Gram‑positive–targeted antibiotics, including candidates for Clostridioides difficile and other priority pathogens. The company has already sold $9.2 million of stock to Lincoln Park and may sell up to an additional $2.8 million, with proceeds intended for working capital, research and development, and general corporate purposes. Existing holders face potential dilution, and Lincoln Park is deemed an underwriter for these resale shares.
Positive
- None.
Negative
- None.
